U-Neuron Biomedical

U-Neuron Biomedical Assets per Share

The Total Assets per Share of U-Neuron Biomedical (6973.TWO) as of Nov 4, 2026 is 21.41 TWD. In the previous year, Total Assets per Share was 13.23 TWD — a change of 61.84% (higher).

Assets per Share

21.41TWD

YoY

61.84%

Last updated:

Total Assets per Share of U-Neuron Biomedical is 2024 21.41 TWD. Total Assets per Share of U-Neuron Biomedical was 2023 13.23 TWD. It decreases by 61.84% higher compared to the previous year.

The U-Neuron Biomedical Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2021
5.34 TWD
Jan 1, 2022
4.71 TWD
Jan 1, 2023
13.23 TWD
Jan 1, 2024
21.41 TWD
The U-Neuron Biomedical Assets per Share history
YEARAssets per ShareYoY
21.41TWD+61.84%
13.23TWD+180.82%
4.71TWD-11.86%
5.34TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about U-Neuron Biomedical stock

Total Assets per Share of U-Neuron Biomedical is 21.41 TWD in 2024.

Total Assets per Share of U-Neuron Biomedical changed from 13.23 TWD to 21.41 TWD, representing a 61.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — U-Neuron Biomedical

All Key Metrics — U-Neuron Biomedical